John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 63,098 shares at $6.41 ($432K) on 2022-04-13, disclosed to the SEC on 2022-04-13.
Open-market sale of $432k FUSN by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.37 | 2,600 | $19K | 4.4% |
| 2 | $7.10 | 18,255 | $130K | 30.0% |
| 3 | $7.10 | 18,255 | $130K | 30.0% |
| 4 | $6.41 | 11,994 | $77K | 17.8% |
| 5 | $6.41 | 11,994 | $77K | 17.8% |
| Total | $6.85 avg | 63,098 |
| $432K |
| 100% |
| Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |
| FUSN | SELL | 2022-04-01 | $2K | — | Filing → |